A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey

Inclusion criteria : * Adult patients with type 2 diabetes mellitus (≥18 years of age). * Type 2 diabetes mellitus diagnosis ≥1 year. * Treated with ≥1 oral antidiabetics (±glucagon like peptid-1 (GLP-1) analogue) without insulin, for at least 6 months and HbA1c level between 8-11% (insulin-naïve). * Stable antidiabetic treatment for at least 3 months. * Willingness to adherence to treatment and titration (including self-injection, self- monitoring blood glucose \[SMBG\]). * Signed informed consent obtained. Exclusion criteria: * Age \<18 years old. * Type 1 diabetes mellitus. * Having secondary type 2 diabetes mellitus. * Use of any insulin therapy including premix, basal plus/basal bolus regimen from the diagnosis. * History of hypoglycemia unawareness. * Known hypersensitivity/intolerance to insulin glargine or any of its excipients. * Have any condition (including known substance or alcohol abuse or psychiatric disorder) that precludes the patient from following and completing the study protocol. * Use of systemic glucocorticoids for two weeks or more within 12 weeks prior to the time of screening. * Pregnant or lactating women. * Participation in another clinical trial. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.